Author

C. L. Henry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

M. J. Niphakis· 2 shared N. Ngo· 2 shared R. M. Suciu· 2 shared A. Inguva· 1 shared A. J. Firestone· 1 shared A. Long· 1 shared A. M. Pinto· 1 shared A. R. Howell· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPhysiology

M. J. Niphakis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Inflammation causes insulin resistance via interferon regulatory factor 3 (IRF3)-mediated reduction in FAHFA levels

S. Yan, A. Santoro, M. J. Niphakis, A. M. Pinto, C. L. Jacobs, R. Ahmad, R. M. Suciu, B. R. Fonslow, R. B. Herbst-Graham, N. Ngo, C. L. Henry, D. M. Herbst, A. Saghatelian, B. B. Kahn, E. D. Rosen

This study identifies the IRF3/AIG1 axis in adipocytes as a mechanism linking obesity-induced inflammation to insulin resistance and suggests AIG1 inhibition as a therapeutic approach.

bioRxiv · Aug 8, 2023 · PreprintPhysiology

ABHD17 enzymes regulate dynamic plasma membrane palmitoylation and N-Ras-dependent cancer growth

J. R. Remsberg, R. M. Suciu, N. A. Zambetti, T. W. Hanigan, A. J. Firestone, A. Inguva, A. Long, N. Ngo, K. M. Lum, C. L. Henry, S. K. Richardson, M. Predovic, B. Huang, A. R. Howell, M. J. Niphakis, , B. F. Cravatt

This study identifies ABD957, a selective ABHD17 inhibitor, which disrupts N-Ras depalmitoylation and inhibits NRAS-mutant AML growth, suggesting potential as a targeted therapy.

bioRxiv · May 21, 2020Cancer Biology